Cbio A/S Receives European Regulatory Clearance to Begin First-in-Human Clinical Trial of Next-Generation T-Cell Therapy in late-stage Cervical CancerCOPENHAGEN, Denmark, March 12, 2026 (GLOBE NEWSWIRE) -- Cbio A/S today announced that it has received regulatory clearance to begin a first-in-human Phase I/IIa clinical trial of novoleucel, the company’s next-generation T-cell therapy designed to improve immune cell function in cancer patients potentially leading to a more effective treatment.
T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing SecuredSØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.
